Literature DB >> 22507242

Targeting epigenetic mediators of gene expression in thoracic malignancies.

David S Schrump1.   

Abstract

Lung and esophageal cancers and malignant pleural mesotheliomas are highly lethal neoplasms that are leading causes of cancer-related deaths worldwide. Presently, limited information is available pertaining to epigenetic mechanisms mediating initiation and progression of these neoplasms. The following presentation will focus on the potential clinical relevance of epigenomic alterations in thoracic malignancies mediated by DNA methylation, perturbations in the histone code, and polycomb group proteins, as well as ongoing translational efforts to target epigenetic regulators of gene expression for treatment of these neoplasms. This article is part of a Special Issue entitled: Chromatin in time and space.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507242      PMCID: PMC6310137          DOI: 10.1016/j.bbagrm.2012.03.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells.

Authors:  Linbo Gao; David Cheng; Jie Yang; Renyi Wu; Wenji Li; Ah-Ng Kong
Journal:  J Nutr Biochem       Date:  2018-02-09       Impact factor: 6.048

3.  ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

Authors:  Vivek Shukla; Mahadev Rao; Hongen Zhang; Jeanette Beers; Darawalee Wangsa; Danny Wangsa; Floryne O Buishand; Yonghong Wang; Zhiya Yu; Holly S Stevenson; Emily S Reardon; Kaitlin C McLoughlin; Andrew S Kaufman; Eden C Payabyab; Julie A Hong; Mary Zhang; Sean Davis; Daniel Edelman; Guokai Chen; Markku M Miettinen; Nicholas P Restifo; Thomas Ried; Paul A Meltzer; David S Schrump
Journal:  Cancer Res       Date:  2017-09-21       Impact factor: 12.701

4.  Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.

Authors:  Mary Zhang; Julie A Hong; Tricia F Kunst; Colleen D Bond; Cara M Kenney; Cheryl L Warga; Javier Yeray; Min-Jung Lee; Akira Yuno; Sunmin Lee; Markku Miettinen; R Taylor Ripley; Chuong D Hoang; Sacha Gnjatic; Jane B Trepel; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2021-07

Review 5.  Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer.

Authors:  Kenneth Huffman; Elisabeth D Martinez
Journal:  Front Oncol       Date:  2013-09-09       Impact factor: 6.244

Review 6.  Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy.

Authors:  Marko Jakopovic; Anish Thomas; Sanjeeve Balasubramaniam; David Schrump; Giuseppe Giaccone; Susan E Bates
Journal:  Front Oncol       Date:  2013-10-09       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.